Traduction de «Médicament essentiel à la survie » (Français → Anglais) :

25. Welcomes India's commitment to a strong IPR regime and to the use of TRIPS flexibilities in international and domestic legislation in order to meet its public health obligations, particularly in relation to access to essential medicines; encourages India rigorously to implement and enforce that regime, while improving access to essential medicines; calls on the EU and India to ensure that commitments under the FTA do not preclude access to essential medicines while India is developing its capacity in changing over from a generic to a research-based industry; supports cooperation between the EU and India in their respective researc ...[+++]h-based pharmaceutical industries, with a view to ensuring mutually beneficial growth therein;

24. Welcomes India’s commitment to a strong IPR regime and to the use of TRIPS flexibilities in international and domestic legislation in order to meet its public health obligations, particularly in relation to access to essential medicines; encourages India rigorously to implement and enforce that regime, while improving access to essential medicines; calls on the EU and India to ensure that commitments under the FTA do not preclude access to essential medicines while India is developing its capacity in changing over from a generic to a research-based industry; supports cooperation between the EU and India in their respective researc ...[+++]h-based pharmaceutical industries, with a view to ensuring mutually beneficial growth therein;

6. Urges the Commission to take an immediate initiative at WTO level for a moratorium on the TRIPS provisions planned to enter into force by 1 January 2005, which will impede the production of generic drugs that are essential for the survival of millions of people in developing countries;

5. Urges the Commission to take an immediate initiative at WTO level for a moratorium on the application of the TRIPS provisions on 1 January 2005, which will prevent the continuation and development of the production and use of generic drugs, which are essential for the survival of millions of people worldwide;

Many of the poorest developing countries are in urgent need of access to affordable essential medicines for treatment of communicable diseases. These countries are heavily dependant on imports of medicines as local manufacturing is scarce.

It enables us to take several steps forward in a debate that is essential for the very survival of part of the world. It also clarifies Parliament’s position on many crucial points such as the need to significantly increase resources assigned to improving health systems and to fighting communicable diseases in developing countries, the will to overcome the opposition between prevention and treatment, which are two essential and complementary aspects of the fight against disease, and the emergence of a new concept of public health as a ...[+++] global public asset. In addition, it clarifies and provides an interpretation of the safeguard clauses in the TRIPS agreement on intellectual property. It also confirms the fact that the issue of the price of drugs is at the heart of the debates on access to treatment and the importance of research and development and, above all, it stresses the need to focus efforts on diseases that particularly affect the South, as well as forgotten illnesses.